The direct costs of treating human visceral leishmaniasis in Brazil

Página do item simplificado
dc.creatorTália Santana Machado de Assis
dc.creatorDian Carlos Pinheiro Rosa
dc.creatorEliane de Morais Teixeira
dc.creatorGlaucia Fernandes Cota
dc.creatorAndré Luís Ferreira Azeredo-da-Silva
dc.creatorGuilherme Werneck
dc.creatorAna Rabello
dc.date.accessioned2024-11-27T23:55:59Z
dc.date.accessioned2025-09-08T23:49:39Z
dc.date.available2024-11-27T23:55:59Z
dc.date.issued2017
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.description.sponsorshipOutra Agência
dc.format.mimetypepdf
dc.identifier.doi10.1590/0037-8682-0133-2017
dc.identifier.issn0037-8682
dc.identifier.urihttps://hdl.handle.net/1843/78336
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofRevista da Sociedade Brasileira de Medicina Tropical
dc.rightsAcesso Aberto
dc.subjectTerapêutica
dc.subjectCustos e Análise de Custo
dc.subjectLeishmaniose Visceral
dc.titleThe direct costs of treating human visceral leishmaniasis in Brazil
dc.typeArtigo de periódico
local.citation.epage482
local.citation.issue4
local.citation.spage478
local.citation.volume50
local.description.resumoINTRODUCTION: The drugs available for visceral leishmaniasis (VL) treatment in Brazil have specific characteristics in terms of operability, effectiveness, toxicity, and cost. The aim of this study was to estimate the direct costs of therapies recommended by the Ministry of Health (MH) for VL treatment in Brazil. METHODS: The analytical perspective used was that adopted by the Brazilian Public Health System. Three drugs and four regimens were included: 1) N-methyl glucamine antimoniate intramuscularly at 20mg per kg per day for 30 days; 2) N-methyl glucamine antimoniate intravenously at 20mg per kg per day for 30 days; 3) amphotericin B deoxycholate at 1mg per kg per day for 21 days; and 4) liposomal amphotericin B at 3mg per kg per day for a 7 days treatment. RESULTS: The estimated direct costs of treatment for an adult patient using N-methylglucamine antimoniate administered via the intramuscular and intravenous routes were USD 418.52 and USD 669.40, respectively. The estimated cost of treatment with amphotericin B deoxycholate was USD 1,522.70. Finally, the estimated costs of treatment with liposomal amphotericin B were USD 659.79, and USD 11,559.15 using the price adopted by the WHO and the Drug Regulation Board, respectively. CONCLUSIONS: This analysis indicates the economic feasibility of replacing N-methyl glucamine antimoniate with liposomal amphotericin B, which allows a shorter treatment period with less toxicity compared with other treatments, provided that the purchase value used by the WHO and transferred to the MH is maintained.
local.publisher.countryBrasil
local.publisher.departmentMEDICINA - FACULDADE DE MEDICINA
local.publisher.initialsUFMG
local.url.externahttps://www.scielo.br/j/rsbmt/a/NPPfmH6yZWqgf9ghNrdP6mK/#

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
The direct costs of treating human visceral leishmaniasis in Brazil.pdf
Tamanho:
878.06 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG